Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por
Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or
Intercept Pharma is facing an uphill battle to get FDA approval of its OCA therapy for non-alcoholic steatohepatitis (NASH) once again, after FDA advisors comprehensively
Intercept Pharma’s hope that its OCA candidate could become the first FDA-approved drug to treat non-alcoholic steatohepatitis (NASH) is starting to look decidedly faint.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh